Skip to main content
OpenTrials
Completed

NCT Number: NCT00121069

Study of Escitalopram in the Treatment of Specific Phobia

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Phobic Disorders Anxiety Disorders Mental Disorders Phobia, Specific

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center

Durham, North Carolina, 27710, United States

About this study

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 18-65 years of age
  • DSM-IV criteria for specific phobia according to the MINI
  • For women of childbearing potential, a negative serum pregnancy test at screening
  • Written informed consent

Exclusion criteria

  • Any current primary DSM-IV diagnosis other than specific phobia
  • History of DSM-IV substance abuse or dependence within the last months
  • Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
  • Suicide risk or serious suicide attempt within the last year
  • Clinically significant laboratory or EKG abnormality or unstable medical condition
  • For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
  • Subjects needing concurrent use of psychotropic medications

Treatment and study plan

Escitalopram

Drug

Primary outcomes

  1. Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline

Secondary outcomes

  1. Response based on CGI-I category

Sponsors and collaborators

Lead sponsor

Connor, Kathryn M., M.D.

Indiv

Collaborators

  • Forest Laboratories

Registry information

Official study title

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

Important dates

Study start
2002
Study completion
2004
First posted
Jul 21, 2005
Registry last updated
Jul 21, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.